Top Markets
Coin of the day
Damora Therapeutics, Inc. Damora Therapeutics, Inc.

Damora Therapeutics, Inc.

DMRA
Clasificación en acciones #6696
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering... Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Precio por acción
$30.90
Última sincronización: 2026-08-27
Capitalización bursátil
$1.90B
Cambio (1 día)
1.68%
Cambio (1 año)
859.63%
País
US
Comercio Damora Therapeutics, Inc. (DMRA)

Categoría

Ganancias de Damora Therapeutics, Inc. (DMRA)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Damora Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Damora Therapeutics, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH